Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124221) titled 'A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets' on Aug. 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Condition:
Hyperprolactinemia
Intervention:
Drug: Cabergoline tablets
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 30, 2025
Target Sample Size: 382
Countries of Recruitment:
China
To ...